Efficacy of perampanel: a review of clinical trial data
Version of Record online: 11 MAR 2013
© 2013 John Wiley & Sons A/S.
Acta Neurologica Scandinavica
Special Issue: Perampanel. Publication of this supplement was supported by Eisai.
Volume 127, Issue Supplement s197, pages 25–29, April 2013
How to Cite
Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand: 2013: 127 (Suppl. 197): 25–29. © 2013 John Wiley & Sons A/S., .
- Issue online: 11 MAR 2013
- Version of Record online: 11 MAR 2013
- Manuscript Accepted: 4 JAN 2013
- Eisai Inc
- AMPA antagonist;
The efficacy of adjunctive perampanel has been investigated in an extensive clinical development program across a broad, multinational population of patients with refractory partial-onset seizures. Further to the results of two Phase II dose-finding studies, perampanel was evaluated in three large Phase III registration studies at the predicted no-effect dose of 2 mg/day and the predicted effective doses of 4, 8, and 12 mg/day. In all three studies, perampanel 4, 8, and 12 mg/day consistently provided significant reductions in the frequency of partial-onset seizures compared with placebo. Improvements in responder rates and seizure freedom rates were also observed. In addition, data from recent interim analyses of extension studies have indicated that these efficacy outcomes may be maintained with long-term treatment. Overall, these studies form a solid evidence base to support the efficacy of adjunctive perampanel in the treatment of refractory partial-onset seizures.